The stock of Neos Therapeutics Inc (NASDAQ:NEOS) hit a new 52-week low and has $5.56 target or 11.00% below today’s $6.25 share price. The 8 months bearish chart indicates high risk for the $95.92 million company. The 1-year low was reported on Oct, 18 by Barchart.com. If the $5.56 price target is reached, the company will be worth $10.55 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 43,211 shares traded hands. Neos Therapeutics Inc (NASDAQ:NEOS) has declined 39.04% since March 15, 2016 and is downtrending. It has underperformed by 44.53% the S&P500.
Analysts await Neos Therapeutics Inc (NASDAQ:NEOS) to report earnings on November, 8. They expect $-1.61 earnings per share, down 159.68% or $0.99 from last year’s $-0.62 per share. After $-1.58 actual earnings per share reported by Neos Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.90% negative EPS growth.
Neos Therapeutics Inc (NASDAQ:NEOS) Ratings Coverage
Out of 4 analysts covering Neos Therapeutics (NASDAQ:NEOS), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $35 is the highest target while $26 is the lowest. The $30.33 average target is 385.28% above today’s ($6.25) stock price. Neos Therapeutics has been the topic of 8 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The rating was initiated by BMO Capital Markets with “Outperform” on Wednesday, June 29. RBC Capital Markets maintained the shares of NEOS in a report on Thursday, November 12 with “Outperform” rating. JMP Securities initiated the stock with “Market Outperform” rating in Monday, August 17 report. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. RBC Capital Markets initiated the stock with “Outperform” rating in Monday, August 17 report. BMO Capital Markets initiated Neos Therapeutics Inc (NASDAQ:NEOS) rating on Monday, August 17. BMO Capital Markets has “Outperform” rating and $26 price target. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Outperform” rating given on Friday, February 19 by Wells Fargo.
According to Zacks Investment Research, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.”
More notable recent Neos Therapeutics Inc (NASDAQ:NEOS) news were published by: Prnewswire.com which released: “NEOS THERAPEUTICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who …” on September 20, 2016, also Quotes.Wsj.com with their article: “News Neos Therapeutics Inc.NEOS” published on April 22, 2015, Prnewswire.com published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on September 19, 2016. More interesting news about Neos Therapeutics Inc (NASDAQ:NEOS) were released by: Globenewswire.com and their article: “Neos Therapeutics Receives Complete Response Letter From the FDA for Cotempla …” published on November 10, 2015 as well as Globenewswire.com‘s news article titled: “Neos Therapeutics Announces Pricing of Initial Public Offering” with publication date: July 23, 2015.
NEOS Company Profile
Neos Therapeutics, Inc., incorporated on June 15, 2009, is a pharmaceutical company. The Firm is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. The Company’s segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. The Firm has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). The Company’s product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. The Company’s branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. The Company’s modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.